ADG 138
Alternative Names: ADG-138; HER2×CD3 POWERbody™Latest Information Update: 22 May 2022
At a glance
- Originator Adagene
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2022 Pharmacodynamics and pharmacokinetics data from preclinical study in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR- 2022)
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in cancer released by Adagene
- 08 Mar 2022 Preclinical trials in Solid tumours (Combination therapy) in China (Parenteral)